Venlafaxine and paroxetine in treatment-resistant depression. Double- blind, randomised comparison

British Journal of Psychiatry

Volumn 175, Issue JUL., 1999, Pages 12-16

  Poirier, M F ^a   Boyer, P ^b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0033059545     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.175.1.12     Document Type: Article

References (25)

1. Andersen, I. M. & Tomenson, B. M. (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. journal of Psychopharmacology, 8, 238-249.
2. Benkert, O., Gründer, G.,Wetzel, H., et al (1996) A randomised double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 30,441-451.
3. _, Szegedi, A., Wetzel, H., et al (1997) Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatrien Scandinavica, 95, 288-296.
4. Clerc, G. E., Ruimy, P. & Verdeau.Paillès, J. (1994) A double-blind comparison of venlafaxine and fluoxetinf in patients hospitalised for major depression and melancholia. International Clinical Psychopharmacology, 9,139-143.
5. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine; a controlled multicenter study. Psychopharmacology, 90,131-138.
6. _ (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289-299.
7. Danjou, P. & Hackett, D. (1995) Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacology, 10 (suppl. 2), 15-20.
8. de Montigny. C. (1999) Venlafaxine in treatment-resistant major depression: A Canadian multicentre open-label trial, journal of Clinical Psychopharmacohgy, in press.
9. Dierick, M., Ravizza, L., Realini, R., et al (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology end Biological Psychiatry, 20, 57-71.
10. Dinan, T. (1995) Treatment approaches to therapy-resistant depression. Journal of Psychopharmacology, 9 (suppl.), 199-204.
11. _ & Burnett, F. (1997) Venlafaxine: pharmacology, clinical efficacy and tolerability of a serotonin-noradrenaline reuptake inhibitor. Journal of Serotonin Research, 3. 203-221.
12. Dunner, D. L. & Dunbar, G. C. (1992) Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry. 53(suppl.2). 21-26.
13. Guelfi, J. D.,White, C., Hackett, D., et al (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56,450-458.
14. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacohgy. Revised DHEW Pub. (ADM). Rockville, MD: National Institute of Mental Health.
15. Hamilton, M. (I960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
16. Keller, M. B., Harrison,W., Fawcett, J. A., et al (1995) Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacology Bulletin, 31, 205-212.
17. Klerman, G. L., Weissman, M. M., Frank, E., et al (1994) Evaluating drug treatments of depressive disorders. In Clinical Evaluation of Psychotmpic Drugs: Principles and Guidelines (eds R. F. Prien & D. S. Robinson), pp. 281-325. New York: Raven Press.
18. Leerubier, Y., Moon, C. A. L., Schifano, F., et al (1997) Double-blind, randomized, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with mild to moderate depression. Acta Psychiatrica Scandinavica, 95, 485-493.
19. Lydiard, R. B. (1985) Tricyclic-resistant depression: Treatment resistant or inadequate treatment? Journal of Clinical Psychiatry. 46, 412-417.
20. Nierenberg, A. A., Feighner, J. P., Rudolph, R., et of (1994) Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 14, 419-423.
21. SAS Institute, Inc. (1989) SAS/STAT Release 6, User's Manual. Gary, NC: SAS Institute.
22. Thase, M. E. & Kupfer, D. J. (1987) Characteristics of treatment-resistant depression. In Treating Resistant Depression (eds J. Zohar & R. H. Belmaker). pp. 23-45. New York: PMA Publishing.
23. _, Rush, A. J., Kasper, S., et al (1995) Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression, 2, 152-168.
24. Tyke, A., Beaumont, G., Bowden, M., et al (1997) A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry. 3, 51-58.
25. Tyrer, P., Marsden, C. A., Casey. P., et al (1987) Clinical efficacy of paroxetine in resistant depression. Journal of Psychopharmacology. I, 251-257.